745 related articles for article (PubMed ID: 23046583)
1. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
2. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
4. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
5. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
[TBL] [Abstract][Full Text] [Related]
6. An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions.
Matsuoka T; Fujii N; Kondo A; Iwaki A; Hokonohara T; Honda H; Sasaki K; Suzuki SO; Iwaki T
Neuropathology; 2011 Feb; 31(1):71-6. PubMed ID: 20573033
[TBL] [Abstract][Full Text] [Related]
7. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
[TBL] [Abstract][Full Text] [Related]
8. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
9. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
[TBL] [Abstract][Full Text] [Related]
10. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation.
Suzuki N; Kato S; Kato M; Warita H; Mizuno H; Kato M; Shimakura N; Akiyama H; Kobayashi Z; Konno H; Aoki M
J Neuropathol Exp Neurol; 2012 Sep; 71(9):779-88. PubMed ID: 22878663
[TBL] [Abstract][Full Text] [Related]
11. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
12. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations.
Bäumer D; Hilton D; Paine SM; Turner MR; Lowe J; Talbot K; Ansorge O
Neurology; 2010 Aug; 75(7):611-8. PubMed ID: 20668261
[TBL] [Abstract][Full Text] [Related]
13. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
14. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
Deng HX; Zhai H; Bigio EH; Yan J; Fecto F; Ajroud K; Mishra M; Ajroud-Driss S; Heller S; Sufit R; Siddique N; Mugnaini E; Siddique T
Ann Neurol; 2010 Jun; 67(6):739-48. PubMed ID: 20517935
[TBL] [Abstract][Full Text] [Related]
15. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
[TBL] [Abstract][Full Text] [Related]
16. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
[TBL] [Abstract][Full Text] [Related]
17. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.
Neumann M; Roeber S; Kretzschmar HA; Rademakers R; Baker M; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):605-16. PubMed ID: 19669651
[TBL] [Abstract][Full Text] [Related]
18. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
[TBL] [Abstract][Full Text] [Related]
19. The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease.
Armstrong RA; Gearing M; Bigio EH; Cruz-Sanchez FF; Duyckaerts C; Mackenzie IR; Perry RH; Skullerud K; Yokoo H; Cairns NJ
Acta Neuropathol; 2011 Feb; 121(2):219-28. PubMed ID: 20886222
[TBL] [Abstract][Full Text] [Related]
20. FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.
Page T; Gitcho MA; Mosaheb S; Carter D; Chakraverty S; Perry RH; Bigio EH; Gearing M; Ferrer I; Goate AM; Cairns NJ; Thorpe JR
J Mol Neurosci; 2011 Nov; 45(3):409-21. PubMed ID: 21603978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
